The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...

Chemoendocrine therapy shows a greater negative association with patient-reported cognitive decline than endocrine therapy ...

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Like SERMs, fulvestrant binds to estrogen receptors and blocks the effects of estrogen on cancer cells. However, because it binds extremely tightly to the estrogen receptor, it causes the receptor to ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...